DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy

Argyrakopoulou, Georgia; Doupis, John

doi:10.1007/s12325-009-0009-6

Cited by 10 publications

(4 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sitagliptin as a novel T2DM therapy improves alpha islet function due to the increased concentrations of active GLP-1, which stimulates insulin secretion and inhibits glucagon secretion. 47 In one study, 48 sitagliptin (100 mg) reduced HbA 1c by 0.6% from a baseline of 7.7% in 555 subjects. Another study, 49 comprising 743 subjects, reported that sitagliptin reduced HbA 1c by 0.8% from a baseline of 7.8%.…”

Section: Discussionmentioning

confidence: 99%

Risk of diarrhea in patients with type 2 diabetes mellitus treated with sitagliptin: a meta-analysis of 30 randomized clinical trials

Zhao¹,

Hong²,

Zheng³

et al. 2014

DDDT

View full text Add to dashboard Cite

BackgroundSitagliptin is an important drug used for diabetes treatment and is used as a monotherapy in diabetic patients. However, there are also reported cases of diarrhea with sitagliptin use. Unfortunately, data concerning the relationship of diarrhea with sitagliptin use in various conditions have yet to be identified. Therefore, the overall incidence and risk of diarrhea with sitagliptin use have not been well defined.MethodsWe conducted searches on Embase, PubMed, and the Cochrane Library databases for relevant randomized controlled trials. Registered relevant trials at the clinical trials registration website were also searched. Statistical analyses were conducted to calculate the overall incidence, odds ratios, and 95% confidence intervals (CI) by using either random-effects or fixed-effect models according to the heterogeneity of the included studies.ResultsA total of 8,891 subjects with diabetes from 30 randomized clinical trials were included in the meta-analysis. The overall incidence of sitagliptin-associated diarrhea was 4.48% (95% CI: 3.59%–5.58%). Compared with the controls, the use of sitagliptin was not associated with a significantly increased risk of diarrhea with an odds ratio of 1.10 (95% CI: 0.78%–1.55%; P=0.58). No evidence of publication bias was observed.ConclusionOur study has shown that there is no difference in diarrhea risk between sitagliptin and controlled therapies. Moreover, sitagliptin is not a medicine that potentially increases the risk of diabetic diarrhea. More studies are recommended to further investigate this association.

show abstract

Section: Discussionmentioning

confidence: 99%

Risk of diarrhea in patients with type 2 diabetes mellitus treated with sitagliptin: a meta-analysis of 30 randomized clinical trials

Zhao¹,

Hong²,

Zheng³

et al. 2014

DDDT

View full text Add to dashboard Cite

show abstract

“…Notably, greater reductions in HbA1c levels were identified when alogliptin was combined with pioglitazone, without elevating the possibility of hypoglycaemic events ( Deacon, 2011 ). The therapeutic effectiveness of alogliptin-pioglitazone combination deserves attention in the future management of T2DM ( Argyrakopoulou and Doupis, 2009 ).…”

Section: Dpp-4 Inhibitors: Current Statusmentioning

confidence: 99%

DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature

Saini

Sharma

Khan

2023

Front. Mol. Biosci.

View full text Add to dashboard Cite

DPP-4 inhibition is an interesting line of therapy for treating Type 2 Diabetes Mellitus (T2DM) and is based on promoting the incretin effect. Here, the authors have presented a brief appraisal of DPP-4 inhibitors, their modes of action, and the clinical efficiency of currently available drugs based on DPP-4 inhibitors. The safety profiles as well as future directions including their potential application in improving COVID-19 patient outcomes have also been discussed in detail. This review also highlights the existing queries and evidence gaps in DPP-4 inhibitor research. Authors have concluded that the excitement surrounding DPP-4 inhibitors is justified because in addition to controlling blood glucose level, they are good at managing risk factors associated with diabetes.

show abstract

“…Independently, sitagliptin inhibits the degradation of incretins, GLP-1, and glucose-dependent insulinotropic peptide by inhibiting DPP-4 (a GLP-1-inactivating peptide), which serve to initiate the secretion of postprandial insulin [ 32 , 37 ]. Considering a few clinical trials that investigated the efficacy of sitagliptin, it can be used as a relatively safe antidiabetic treatment that works independently but shows greater effectiveness when administered as an adjunct therapy with BC [ 38 ]. In a 2018 experimental study, induced diabetic rats were treated with BC, sitagliptin 10 mg/kg orally (SG10), sitagliptin 20 mg/kg orally (SG20), and a combination of SG10+BC over two weeks.…”

Section: Reviewmentioning

confidence: 99%

“…For T2DM patients, the PPAR-γ pathway role is diminished, leading to insulin insensitivity [ 39 , 40 ]. Additionally, T2DM patients have a high activity of the Janus kinase (JAK)/signal transducer and activator of transcription proteins (STAT) pathway, which induces the inflammation of endothelial cells via interleukin-6 [ 38 ]. The BC+SG10 treatment results indicated that both pathways were involved.…”

Section: Reviewmentioning

confidence: 99%

Bromocriptine and Colesevelam Hydrochloride: Novel Therapies for Type II Diabetes Mellitus

Soileau,

Nguyen,

Senthil

et al. 2023

Cureus

View full text Add to dashboard Cite

The increasing prevalence of type II diabetes mellitus (T2DM) is a worldwide healthcare concern. Over the years, our understanding of T2DM has grown considerably in uncovering the pathophysiology of the disease and, in turn, understanding how improved treatment methods can be used to slow disease progression. Some long-term complications that are responsible for most T2DM mortalities include cardiovascular disease, neurological decline, and renal failure. In treating T2DM, it is important that not only glycemic control be obtained but also control of associated complications. Bromocriptine and colesevelam hydrochloride have both been approved by the Food and Drug Administration (FDA) to treat T2DM but are not readily used in practice. These medications are known to treat glycemic dysregulation via unconventional mechanisms, which might contribute to their potential to provide protection against common diabetic complications such as cardiovascular disease. In order to ensure that these overlooked medications become more readily used, it is vital that more research be performed to further elucidate their efficacy in a clinical setting. Future studies should continue to provide clinicians a better understanding of the role these medications have on the treatment of T2DM such as their ability to be used in combination with other commonly used T2DM medications or as monotherapies.

show abstract

DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy

Cited by 10 publications

References 48 publications

Risk of diarrhea in patients with type 2 diabetes mellitus treated with sitagliptin: a meta-analysis of 30 randomized clinical trials

Risk of diarrhea in patients with type 2 diabetes mellitus treated with sitagliptin: a meta-analysis of 30 randomized clinical trials

DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature

Bromocriptine and Colesevelam Hydrochloride: Novel Therapies for Type II Diabetes Mellitus

Contact Info

Product

Resources

About